DYNAVAX TECHNOLOGIES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.73 USD | -2.54% |
|
-8.60% | -23.25% |
| May. 08 | Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M | MT |
Presenter SpeechRyan Spencer (Executives)Ladies and gentlemen, I would like to welcome you to ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Calendar
2024-05-23
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.73
USD
Average target price
24.67
USD
Spread / Average Target
+129.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.25% | 1.4B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Transcript : Dynavax Technologies Corporation - Shareholder/Analyst Call